IVUS and Angiography in Left Main PCI: OPTIMAL Trial Show Comparable Outcomes

Written By :  Aashi verma
Published On 2026-04-08 03:30 GMT   |   Update On 2026-04-08 03:31 GMT

A major clinical trial recently demonstrated that intravascular ultrasonography (IVUS) guidance during percutaneous coronary intervention (PCI) yielded similar results regarding long-term clinical outcomes for patients with unprotected left main coronary artery disease. Over a median follow-up of 2.9 years, primary composite endpoints, including stroke and mortality, were statistically similar across both treatment groups.

These findings are published in March 2026 in the New England Journal of Medicine.

The Clinical Burden of Unprotected Left Main Coronary Disease

Percutaneous coronary intervention is increasingly being utilized for the revascularization of unprotected left main coronary artery disease. Because this condition involves the primary artery supplying blood to the heart, procedural precision is vital for long-term survival. While intravascular ultrasonography allows for detailed imaging from within the coronary vessels, clinicians have debated whether this advanced guidance actually improves patient outcomes compared to conventional angiographic guidance alone. This international study sought to resolve this uncertainty within a large clinical setting.

Study Overview

In the international, multicenter, open-label trial, known as the OPTIMAL study, 806 patients were randomized in a 1:1 ratio. The study population, which had a mean age of 71.4 years (plus or minus a standard deviation of 10.7), included a significant proportion of patients with diabetes (34.7%) and was predominantly male (78.4%). Half of the participants received IVUS-guided PCI, while the remaining half underwent standard angiography-guided procedures. The primary endpoint measured was a patient-oriented composite of any stroke, any myocardial infarction (heart attack), any revascularization, or death from any cause. The trial was funded by Philips Image Guided Therapy Devices and Boston Scientific.

The Key findings from the study include:

• At a median follow-up of 2.9 years, primary endpoint events occurred in 33.7% of the IVUS-guided group and 30.9% in the angiography-guided group.

• Statistical analysis showed a hazard ratio of 1.11 and a p-value of 0.40, confirming that the difference between the two groups was not significant.

• The incidence rates of death, myocardial infarction, or the necessity for further revascularization appeared similar across both patient groups.

• Safety profiles remained consistent, with no significant differences noted in procedure-related or overall safety events between the two modalities.

Clinical Relevance and Targeted Guidance

For practicing cardiologists, the study clarifies that IVUS-guided PCI does not necessarily yield superior clinical results compared to traditional angiography in the management of unprotected left main coronary artery disease. Despite the technological appeal of intravascular imaging, the trial suggests that standard angiographic techniques achieve comparable safety and efficacy profiles over a nearly three-year period. These findings underscore that clinicians should focus on overall procedural excellence, as the choice between these two guidance methods did not significantly impact the long-term risk of stroke, heart attack, or mortality.

Reference:

Testa L, De la Torre Hernandez JM, De Maria GL, et al. IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease. New England Journal of Medicine. 2026 Mar 30.



Tags:    
Article Source : New England Journal of Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News